Head to Head Analysis: PhaseBio Pharmaceuticals (NASDAQ:PHAS) Vs. Alpine Immune Sciences (NASDAQ:ALPN)
Head to Head Analysis: PhaseBio Pharmaceuticals (NASDAQ:PHAS) Vs. Alpine Immune Sciences (NASDAQ:ALPN)
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) and Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.
相生物制药(纳斯达克：PHAS-GET评级)和高山免疫科学(纳斯达克：ALPN-GET评级)都是小盘医疗公司，但哪种投资更好？我们将根据这两家公司的风险、估值、机构所有权、分析师建议、收益、盈利能力和股息等方面的实力进行比较。
Institutional & Insider Ownership
机构与内部人持股
49.0% of PhaseBio Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Alpine Immune Sciences shares are held by institutional investors. 9.9% of PhaseBio Pharmaceuticals shares are held by insiders. Comparatively, 54.7% of Alpine Immune Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
PhaseBio PharmPharmticals 49.0%的股份由机构投资者持有。相比之下，阿尔卑斯免疫科学公司79.0%的股份由机构投资者持有。PhaseBio PharmPharmticals 9.9%的股份由内部人士持有。相比之下，阿尔卑斯免疫科学公司54.7%的股份由内部人士持有。强大的机构持股表明，捐赠基金、大型基金经理和对冲基金相信，从长期来看，一只股票的表现将好于大盘。
Profitability
盈利能力
This table compares PhaseBio Pharmaceuticals and Alpine Immune Sciences' net margins, return on equity and return on assets.
此表比较了PhaseBio制药公司和阿尔卑斯免疫科学公司的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| PhaseBio Pharmaceuticals | -12,572.13% | N/A | -174.38% |
| Alpine Immune Sciences | -169.82% | -47.34% | -23.12% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| PhaseBio制药公司 | -12,572.13% | 不适用 | -174.38% |
| 阿尔卑斯山免疫科学 | -169.82% | -47.34% | -23.12% |
Analyst Recommendations
分析师建议
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PhaseBio Pharmaceuticals | 0 | 5 | 0 | 0 | 2.00 |
| Alpine Immune Sciences | 0 | 0 | 3 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| PhaseBio制药公司 | 0 | 5 | 0 | 0 | 2.00 |
| 阿尔卑斯山免疫科学 | 0 | 0 | 3 | 0 | 3.00 |
PhaseBio Pharmaceuticals currently has a consensus target price of $4.50, suggesting a potential upside of 4,636.84%. Alpine Immune Sciences has a consensus target price of $15.67, suggesting a potential upside of 157.68%. Given PhaseBio Pharmaceuticals' higher probable upside, equities analysts clearly believe PhaseBio Pharmaceuticals is more favorable than Alpine Immune Sciences.
PhaseBio制药公司目前的共识目标价为4.50美元，这意味着潜在的上涨幅度为4636.84%。阿尔卑斯免疫科学公司的共识目标价为15.67美元，暗示潜在上涨157.68%。鉴于PhaseBio制药公司更有可能上行，股票分析师显然认为PhaseBio制药公司比阿尔卑斯免疫科学公司更有利。
Risk and Volatility
风险和波动性
PhaseBio Pharmaceuticals has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500. Comparatively, Alpine Immune Sciences has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.
PhaseBio PharmPharmticals的贝塔系数为2.87，这表明其股价的波动性比标准普尔500指数高187%。相比之下，阿尔卑斯山免疫科学公司的贝塔系数为1.5，这表明其股价的波动性比标准普尔500指数高50%。
Valuation & Earnings
估值与收益
This table compares PhaseBio Pharmaceuticals and Alpine Immune Sciences' gross revenue, earnings per share (EPS) and valuation.
此表比较了PhaseBio制药公司和阿尔卑斯免疫科学公司的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PhaseBio Pharmaceuticals | $10.83 million | 0.44 | -$131.07 million | ($2.13) | -0.04 |
| Alpine Immune Sciences | $23.44 million | 7.89 | -$50.33 million | ($1.92) | -3.17 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| PhaseBio制药公司 | 1083万美元 | 0.44 | -1.3107亿美元 | ($2.13) | -0.04 |
| 阿尔卑斯山免疫科学 | 2344万美元 | 7.89 | -5,033万元 | ($1.92) | -3.17 |
Alpine Immune Sciences has higher revenue and earnings than PhaseBio Pharmaceuticals. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than PhaseBio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
阿尔卑斯免疫科学公司的收入和收益高于PhaseBio制药公司。阿尔卑斯免疫科学的市盈率低于PhaseBio PharmPharmticals，这表明它目前是两只股票中更负担得起的一只。
Summary
摘要
Alpine Immune Sciences beats PhaseBio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
阿尔卑斯免疫科学公司在两只股票之间的14个因素中有10个超过了PhaseBio制药公司。
About PhaseBio Pharmaceuticals
关于PhaseBio制药公司
(Get Rating)
(获取评级)
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
PhaseBio制药公司是一家临床阶段的生物制药公司，致力于心血管疾病新疗法的开发和商业化。该公司正在筹备中的药物包括：用于抗血小板治疗替卡格雷的新型逆转药bentracimab(PB2452)，用于治疗肺动脉高压的每周一次的血管活性肠肽受体激动剂pemziviptadil(PB1046)，以及用于治疗顽固性高血压的口服药物PB6440。该公司由阿舒托什·奇尔科蒂和克莱·贝尔纳丁·索普于2002年1月创立，总部设在宾夕法尼亚州马尔文。
About Alpine Immune Sciences
关于阿尔卑斯免疫科学
(Get Rating)
(获取评级)
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
阿尔卑斯免疫科学公司是一家临床阶段的生物制药公司，专注于发现和开发基于蛋白质的免疫疗法，用于治疗癌症、自身免疫/炎症性疾病和其他疾病。其产品线包括用于治疗自身免疫和炎症性疾病的可诱导T细胞共刺激因子(ICOS)/分化簇28(CD28)拮抗剂计划ALPN-101；用于治疗癌症的条件性CD28共刺激因子和双重检查点抑制剂ALPN-202；以及用于治疗B细胞介导性炎症和自身免疫性疾病的双重B细胞细胞因子拮抗剂ALPN-303。该公司与AbbVie爱尔兰无限公司签署了开发ALPN-101的合作协议，并与Adaptimmune Treateutics plc达成了开发下一代Spear T细胞产品的合作协议。阿尔卑斯免疫科学公司成立于2007年，总部设在华盛顿州西雅图。
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得PhaseBio制药日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对PhaseBio制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。